StockNews.com Initiates Coverage on Nabriva Therapeutics (NASDAQ:NBRV)
by Teresa Graham · The Cerbat GemEquities researchers at StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Free Report) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Nabriva Therapeutics Stock Performance
Nabriva Therapeutics has a 1 year low of $1.22 and a 1 year high of $8.45. The company’s 50 day simple moving average is $0.14. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. The stock has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53.
Nabriva Therapeutics Company Profile
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.
Featured Stories
- Five stocks we like better than Nabriva Therapeutics
- Upcoming IPO Stock Lockup Period, Explained
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- MarketBeat Week in Review – 6/24 – 6/28
- Investing in large cap stocks: Diving into big caps
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024